60 Degrees Pharmaceuticals (SCTP) investor relations material

Commercial product overview and market context

• ARAKODA is FDA-approved for malaria prevention and has been commercially available in the U.S. since Q3 2019.

• Initial commercialization was impacted by the pandemic, but sales have grown, especially due to off-label use for chronic babesiosis.

• Gross profit margins have stabilized, and the company aims to expand sales through both malaria and babesiosis indications.

• Market research shows positive feedback from patients and physicians, with barriers including generic alternatives and required blood tests.

• Commercial efforts are expanding with more virtual sales reps, partnerships for affordability, and consumer outreach programs.

Babesiosis research and clinical development

• Chronic babesiosis has emerged as a significant driver of sales, with about 70% of prescriptions linked to this indication.

• Tafenoquine, the active ingredient in ARAKODA, has shown promise in clearing Babesia parasites, supported by case series and early clinical data.

• Three clinical trials are underway: a randomized controlled study, an expanded access study, and a chronic disease study.

• Early results indicate clinical benefit and parasite clearance, with further validation ongoing using FDA-licensed diagnostics.

• The company expects to reach key enrollment and interim analysis milestones in late 2024, with a potential NDA submission in Q1 2027.

Strategic outlook and investor milestones

• The babesiosis market opportunity is estimated to be 4-5 times larger than malaria prevention.

• Key upcoming milestones include diagnostic proof of chronic babesiosis and interim analysis results from the hospital study.

• Expanded commercial access programs will provide new sales data to inform future strategy.

• Regulatory strategy for babesiosis is expected to be disclosed in Q4 2024.

• Having an approved product allows the company to refine commercial strategies and positions it for sustainable growth.